mafosfamide has been researched along with African Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| B Agus, D; Chen, PY; Christofk, H; Ferrari, R; Fitz-Gibbon, S; Flinders, C; Lam, L; Mallick, P; Pellegrini, M; Rubbi, L; Ruderman, D; Thompson, M | 1 |
| Binet, C; Brémond, JL; Chassaigne, M; Colombat, P; Domenech, J; Georget, MT; Gihana, E; Lamagnère, JP | 1 |
2 other study(ies) available for mafosfamide and African Lymphoma
| Article | Year |
|---|---|
Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Burkitt Lymphoma; Cell Line, Tumor; Cyclophosphamide; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Mice; Polycomb Repressive Complex 2; Principal Component Analysis; Promoter Regions, Genetic | 2016 |
Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Topics: Bone Marrow; Bone Marrow Cells; Bone Marrow Purging; Burkitt Lymphoma; Cells, Cultured; Cyclophosphamide; Doxorubicin; Drug Synergism; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Stem Cells; Tumor Cells, Cultured | 1992 |